Drugs / CD19CAT-41BBZ CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02935257 | Sep 2017 → Aug 2024 overdue | acute lymphoblastic leukemia | University College, London | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAT-41BBZ CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935257 ↗ |
| Known as | AUTO1 | “We describe the multicenter phase I ALLCAR19 (NCT02935257) study of autologous CAT19-41BB-Z CAR T cells (AUTO1) in relapsed or refractory (r/r) adult B-ALL.” PMID 34464155 ↗ Aug 2021 |
| Known as | CAT19-41BB-Z | “We developed a novel second-generation CD19-CAR (CAT19-41BB-Z) with a fast off rate, designed for more physiologic T-cell activation to reduce toxicity and improve engraftment.” PMID 34464155 ↗ Aug 2021 |
| Known as | CD19CAR T-cells | “CD19CAT-41BBζ CAR T-cells (referred to subsequently as CD19CAR T-cells)” NCT02935257 ↗ |
| Known as | CD19CAT-41BBζ CAR T-cells | “CD19CAT-41BBζ CAR T-cells (referred to subsequently as CD19CAR T-cells)” NCT02935257 ↗ |
| Action | Deplete | “B-cell aplasia ongoing in 15 of 20 patients at last follow-up” PMID 34464155 ↗ Aug 2021 |
| Modality | Cell therapy | “autologous CAT19-41BB-Z CAR T cells (AUTO1)” PMID 34464155 ↗ Aug 2021 |
| Route | Other | “Infusion with CD19CAT-41BBZ CAR T-cells” NCT02935257 ↗ |
| Target | CD19 | “CAR T-cells to Target CD19” NCT02935257 ↗ |